“A Phase III Multicenter Randomized Study of The Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT)”. EudraCT number: 2004-000918-39

A total of 1971 study participants were enrolled in the SILCAAT study from 125 sites in 11 countries around the world. The Copenhagen region enrolled 418 participants from 30 sites in 3 countries.

In November 2008 follow-up of all study participants was finalised, and all sites were officially closed in May/June 2009.
Clarifying whether administration of IL-2 provides clinical protection in HIV-infected populations started more than a decade ago and an enormous number of professionals have worked on answering this research question ever since.

The important findings from the SILCAAT study has been shared with all investigators after the unblinding of the study and the study results have been published in the New England Journal of Medicine, 15 October 2009 

Please refer to “publications” in the menu for the complete list of publications.